[go: up one dir, main page]

WO2007036920A3 - Therapeutic use of polyanhydroglucronic acid - Google Patents

Therapeutic use of polyanhydroglucronic acid Download PDF

Info

Publication number
WO2007036920A3
WO2007036920A3 PCT/IE2006/000104 IE2006000104W WO2007036920A3 WO 2007036920 A3 WO2007036920 A3 WO 2007036920A3 IE 2006000104 W IE2006000104 W IE 2006000104W WO 2007036920 A3 WO2007036920 A3 WO 2007036920A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid
paga
copolymer
salt
polyanhydroglucronic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IE2006/000104
Other languages
French (fr)
Other versions
WO2007036920A2 (en
Inventor
Jiri Briestensky
Ivan Santar
Vladimir Semecky
Petr Nachtigal
Anthony Richardson
Keith Real
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alltracel Dev Services Ltd
Original Assignee
Alltracel Dev Services Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltracel Dev Services Ltd filed Critical Alltracel Dev Services Ltd
Publication of WO2007036920A2 publication Critical patent/WO2007036920A2/en
Publication of WO2007036920A3 publication Critical patent/WO2007036920A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a composition comprising a first component selected from a biocompatible anionic polyanhydroglucuronic acid (PAGA), a salt thereof, a copolymer thereof, and an intermolecular complex thereof, and a second component comprising an anti-lipemic agent. The present invention also provides for use of a biocompatible anionic polyanhydroglucuronic acid (PAGA), a salt thereof, a copolymer thereof or an intermolecular complex thereof, in the preparation of a medicament for the treatment of inflammation and use of a biocompatible anionic polyanhydroglucuronic acid (PAGA), a salt thereof, a copolymer thereof or an intermolecular complex thereof, in the preparation of a medicament for maintaining a patient's blood glucose concentration in a physiological range.
PCT/IE2006/000104 2005-09-28 2006-09-28 Therapeutic use of polyanhydroglucronic acid Ceased WO2007036920A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72107305P 2005-09-28 2005-09-28
US60/721,073 2005-09-28

Publications (2)

Publication Number Publication Date
WO2007036920A2 WO2007036920A2 (en) 2007-04-05
WO2007036920A3 true WO2007036920A3 (en) 2008-03-06

Family

ID=37561165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IE2006/000104 Ceased WO2007036920A2 (en) 2005-09-28 2006-09-28 Therapeutic use of polyanhydroglucronic acid

Country Status (2)

Country Link
IE (1) IE20060710A1 (en)
WO (1) WO2007036920A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20120268A1 (en) * 2012-12-03 2014-06-04 Diopeite Consulting Ltd PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OBESITY

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006405A1 (en) * 1996-08-09 1998-02-19 Raisio Benecol Ltd. Stanol composition and the use thereof
WO2000004907A1 (en) * 1998-07-21 2000-02-03 Alpenstock Holdings Limited An antilipemic formulation
US20020110531A1 (en) * 2001-02-14 2002-08-15 Steven Faust Cholesterol reducing composition and method of making the same
WO2003068245A1 (en) * 2002-02-14 2003-08-21 Alpenstock Holdings Limited Use of polyanhydroglucuronic acid comprising microdispersed oxidised cellulose as immunomodulator

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006405A1 (en) * 1996-08-09 1998-02-19 Raisio Benecol Ltd. Stanol composition and the use thereof
WO2000004907A1 (en) * 1998-07-21 2000-02-03 Alpenstock Holdings Limited An antilipemic formulation
US20020110531A1 (en) * 2001-02-14 2002-08-15 Steven Faust Cholesterol reducing composition and method of making the same
WO2003068245A1 (en) * 2002-02-14 2003-08-21 Alpenstock Holdings Limited Use of polyanhydroglucuronic acid comprising microdispersed oxidised cellulose as immunomodulator

Also Published As

Publication number Publication date
WO2007036920A2 (en) 2007-04-05
IE20060710A1 (en) 2007-07-25

Similar Documents

Publication Publication Date Title
WO2007149310A3 (en) Multiphasic biofunctional nano-components and methods for use thereof
WO2006041942A3 (en) Ocular delivery of polymeric delivery formulations
WO2006002366A3 (en) Biodegradable ocular devices, methods and systems
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
WO2005000161A3 (en) Methods and devices for occluding body lumens and/or for delivering therapeutic agents
EP1586338A3 (en) The use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
WO2009076547A8 (en) Implantable drug delivery device and methods for treatment of the bladder and other body vesicles or lumens
TR200201440T2 (en) Preparation of radium-223 for biomedical use
WO2006062748A3 (en) Omega-3 fatty acids and dyslipidemic agent for lipid therapy
WO2006082588A3 (en) Method and device for ophthalmic administration of active pharmaceutical ingredients
EP2108390A3 (en) Device for local and/or regional delivery employing liquid formulations of therapeutic agents
EP1723976A3 (en) Intraluminal medical devices in combination with therapeutic agents
UA101309C2 (en) Activin-actrii antagonists thereof and uses for increasing red blood cell levels
BRPI0411021A (en) adhesive composition, method for manufacture thereof, medical article, and pharmaceutical administration device
BR0308137A (en) Constant Release Drug Formulations Containing a Vehicle Peptide
CA2505040A1 (en) Composition for iontophoretic delivery of rotigotine
PT2210605T (en) Once daily dosage forms of trospium
WO2002060410A3 (en) Methods for sustained release local delivery of drugs for ablation of unwanted tissue
PL1643999T3 (en) Pyridoxamine for use in the treatment of diabetic neprhopathy in type ii diabetes
WO2007025142A3 (en) Gel compositions comprising a combination of an antiseptic and an anesthetic agent for treating surface areas in medical and surgical procedures
ATE533509T1 (en) HEART-SLOWING DRUG WITH SHORT-TERM BETA-BLOCKERS AS ACTIVE INGREDIENTS
MXPA05008461A (en) Kit for applying drug coating to a medical device in surgeon room.
WO2008088536A8 (en) Differential drug release from a medical device
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
WO2007036920A3 (en) Therapeutic use of polyanhydroglucronic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06796046

Country of ref document: EP

Kind code of ref document: A2